Referenced Papers (4)
Resistance to human immunodeficiency virus 1 infection conferred by a compound CCR5Δ32 and CCR5 C20S heterozygote
Bashar Alkhatib, Mary Jabari, Shymaa Bilasy, Husni Abdul-Rahman, Kamal Sandhu, Stephen Lai
J. Infect. Dis., 2023
"This paper is the source for the presented graphs, which illustrate typical seasonal patterns of various respiratory viruses as observed in the HIVE surveillance cohort study."
Reduced respiratory syncytial virus load, symptoms, and infections: A human challenge trial of MVA-BN-RSV vaccine
Elke Jordan, Golam Kabir, Stephanie Schultz, Günter Silbernagl, Darja Schmidt, Victoria A Jenkins
J. Infect. Dis., 2023
"The speaker references this paper as the work of a graduate student who analyzed RSV antibody dynamics in the HIVE cohort to determine correlates of protection."
Protection from COVID-19 vaccination and prior SARS-CoV-2 infection among children aged 6 months-4 years, United States, September 2022-April 2023
Leora R Feldstein, Jasmine Ruffin, Ryan Wiegand, Lauren Grant, Tara M Babu, Melissa Briggs-Hagen
J. Pediatric Infect. Dis. Soc., 2025
"This paper is referenced to provide data on vaccine effectiveness in very young children (under 6 months), contrasting with the age group primarily discussed."
Effectiveness of bivalent mRNA COVID-19 vaccines in preventing SARS-CoV-2 infection in children and adolescents aged 5 to 17 years
Leora R Feldstein, Amadea Britton, Lauren Grant, Ryan Wiegand, Jasmine Ruffin, Tara M Babu
JAMA, 2024
"This is the primary study discussed by the speaker, demonstrating the effectiveness of the bivalent COVID-19 booster against both symptomatic and asymptomatic infection in children aged 5-12 years."